Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD
Status:
Terminated
Trial end date:
2018-07-27
Target enrollment:
Participant gender:
Summary
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose
study that will investigate the efficacy and safety of 5.6 mg TNX-102 SL (2 x 2.8 mg
tablets)-a sublingual formulation of cyclobenzaprine. Following successful screening and
randomization, eligible patients will have a telephonic visit at week 2 and then return
regularly to the study clinic for monthly visits for assessments of efficacy and safety.